PROGRAM CO-CHAIRS
Lucia M. Novak MSN, CRNP, ANP-BC, BC-ADM, FAANP
President, Diabesity LLC, North Bethesda, Maryland
Co-Executive Director, Capital Health and Metabolic Center, Capital Diabetes and Endocrine Associates,
Silver Spring, Maryland
Diabetologist, Stability Health, Worcester, Massachusetts
Kim Pfotenhauer DO, FACOFP, DABOM
Associate Professor of Family Medicine
Assistant Dean for Clerkship Education
Michigan State University College of Osteopathic Medicine
East Lansing, Michigan
SPEAKING FACULTY
Daniel Moore, MD, PhD
Associate Professor
Pediatrics and Pathology, Microbiology, and Immunology
Vanderbilt University Medical Center
Nashville, Tennessee
Charles Vega, M.D.
Clinical Professor
UC Irvine Department of Medicine
Irvine, California
PATIENT ADVOCATE
Molly Coleman, IPN
Clinical DM Education at Diabetes Care Center
West Monroe, Louisiana
Ashley Cripps
Simsboro, Louisiana
Marissa Loginow
Maryville, Tennessee
Kyle Smythe
McCordsville, Indiana
PROGRAM OVERVIEW
This enduring activity, developed from the proceedings of the DETECT-T1D Nashville summit, provides a practical overview of early detection and disease-modifying therapies across the type 1 diabetes (T1D) continuum. Insights from multidisciplinary expert faculty, paired with powerful patient perspectives, aim to translate emerging evidence into actionable strategies for clinical practice.
The program will cover evidence and guidance for identifying presymptomatic T1D, applying therapies that can delay disease progression, as well as exploring new and emerging strategies to preserve beta-cell function in new onset T1D. This activity also contains additional patient and caregiver perspectives on the continuum of T1D from the Indianapolis and New Orleans DETECT-T1D summits, as well as additional resources for you to explore.
TARGET AUDIENCE
This virtual activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat, or see patients with or at high risk for T1D is needed, including primary care clinicians, pediatricians, pediatric and adult endocrinologists, diabetes educators, infusion professionals, and other allied health care professionals.
LEARNING OBJECTIVES
Upon completion of this enduring activity, attendees will have improved ability to:
- Implement risk-based screening approaches to facilitate timely identification of presymptomatic T1D
- Analyze T1D screening results to determine disease stage and inform appropriate monitoring and referral decisions
- Develop individualized treatment strategies that incorporate disease-modifying therapies to delay T1D progression in eligible patients
- Recognize the importance of beta cell preservation on T1D prognosis and outcomes
- Review emerging approaches aimed at beta cell preservation and their potential future application in new-onset T1D
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 2.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 2.75 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 2.75 CPEU.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Molly Coleman | Has nothing to disclose. |
| Ashley Cripps | Has nothing to disclose. |
| Marissa Loginow | Has nothing to disclose. |
| Daniel Moore, MD, PhD |
Consulting Fees: Sanofi Advisory Board Stock Options: Metaphor Biotechnology |
| Lucia M. Novak MSN, CRNP, ANP-BC, BC-ADM, FAANP |
Consulting Fees: Abbott Diabetes Care, Novo Nordisk, Sanofi US Speakers Bureau: Abbott Diabetes Care, Novo Nordisk, Sanofi US |
| Kim Pfotenhauer DO, FACOFP, DABOM |
Consulting Fees: Novo Nordisk Stock: ROMTech Advisory Board: Boehringer Ingelheim |
| Kyle Smythe |
Has nothing to disclose. |
| Charles Vega, M.D. | Consulting Fee: GSK, Boehringer Ingelheim, Exact Sciences |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Zoe Bloodgood, Medical Education Content Engineer for Med Learning Group has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Sarah Milano, RN, has nothing to disclose
- A medical reviewer from CE Peer Review LLC, has nothing to disclose.
- Marissa Mays-Verman, Senior Program Director for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
- Naomi DeBrito, Program Manager for Med Learning Group, has nothing to disclose.
- Maya Sanford, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Manager for Med Learning Group, has nothing to disclose.
- Melanie Grau, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 19, 2026
EXPIRATION DATE: October 19, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
